radiation oncology and remediumRT
|
Cancer is one of the largest killers globally. Incidence and mortality are growing. In 2018 there were approximately 18 million cancer cases globally with close to 10 million deaths. This is predicted to rise to almost 20 million cases and 12 million deaths by 2025
Radiation Therapy is known to be effective in 60% of cases and curative in 40% of all cases yet this treatment is unavailable to 80% of the worlds’ population There is an estimated shortage of some 20,000 treatment units to treat these cancer cases with radiation therapy remediumRT specialise in assisting our clients to identify needs, create strategies and deliver bespoke radiation oncology solutions There are major issues in developing radiation therapy services globally such as funding, technology implementation and, availability of skilled workforce remediumRT believes that all these barriers can be addressed Modern equipment is the preferred option for advanced curative treatment techniques and highest productivity remediumRT is a Switzerland based consultancy company dedicated to realising advanced technology solutions for radiation oncology |
realising advanced technology solutions for radiation oncology" |
cancer and radiation oncology
|
Cancer is a growing global concern. The International Agency for Research on Cancer (IARC) data published September 2018 shows reported Cancer Incidence of 18.1m cases and 9.6m deaths globally
The Lancet Oncology Commission report published in 2015 predicts Cancer Incidence to increase to 24.6m with 13m global deaths by 2030 There are important principles that are recognised in the cancer care community that should be considered by those who would be interested in investing in a health agenda, and which make cancer a critical investment need Cancer is now the leading cause of early death worldwide. Population ageing, and growth are key drivers contributing to the cancer burden projected increase to 24.6 million cases per annum by 2030 In 2011 the United Nations General Assembly, committed to a programme of prevention and control of Non-Communicable Diseases, by 2035 reducing premature mortality by 25% relative to 2010 levels – cancer would represent 1.5 million deaths per annum saved by 2035 Radiation therapy is used in more than half of all cancer cases with academic papers suggesting as many as 60% of all cancers would derive clinical benefit from radiotherapy Novel therapeutics take 10-15 years to transfer to routine clinical use. In the current climate it is a reasonable assumption that the role of radiation therapy will remain significant in the successful treatment of cancer for many years The Lancet report highlights the need to encourage low to middle income countries (LMICs) to look at investing in radiation oncology to improve health outcomes for their population Radiation therapy is an effective and, non-invasive treatment available to cure cancer With increasing wealth in LMICs, the drive is for those economies to commit more on healthcare to improve outcomes and health of the population – and radiation oncology is a key part of this drive |